Your new experience awaits. Try the new design now and help us make it even better

SYSTEMATIC REVIEW article

Front. Psychiatry

Sec. Mood Disorders

Volume 16 - 2025 | doi: 10.3389/fpsyt.2025.1656969

Clinical efficacy of fecal microbiota transplantation in alleviating depressive symptoms: a Meta-Analysis of randomized trials

Provisionally accepted
Tao  Xiao ZhangTao Xiao ZhangYing  LiYing LiYue  yue GuoYue yue Guo*Jia  SunJia SunYang  YangYang Yang
  • Jiangsu Province Hospital of Chinese Medicine, Nanjing, China

The final, formatted version of the article will be published soon.

Background: Depressive symptoms are common in neuropsychiatric disorders, significantly affecting quality of life and posing challenges to treatment. While pharmacological and psychological therapies remain standard, many patients show limited response. Fecal microbiota transplantation (FMT), which aims to restore gut microbial balance, has emerged as a novel approach for alleviating depressive symptoms by modulating the gut-brain axis. This study aims to conduct a comprehensive synthesis and quantitative evaluation of current 2 evidence to elucidate the therapeutic potential of FMT in the management of depressive symptomatology. Methods: Following PRISMA guidelines, we conducted a systematic search across PubMed, Embase, Web of Science, the Cochrane Library, and CINAHL from January 1, 2000, to December 31, 2024. 12 randomized controlled trials (RCTs) with 681 participants were included. The standardized mean difference (SMD) was calculated to evaluate FMT's effect on depressive symptoms. Subgroup analyses examined effects by delivery routes, follow-up duration, and clinical population. Results: FMT significantly reduced depressive symptoms (SMD = -1.21; 95% CI: -1.87 to -0.55; p = 0.0003). Sensitivity analysis confirmed statistical significance (SMD = -0.56; 95% CI: -0.86 to -0.26; p = 0.001). Both oral capsule and direct gastrointestinal administration were effective, with greater effects seen in direct gastrointestinal delivery (SMD: -1.06 vs -1.29). Improvements were most notable in the short-to mid-term; effects diminished by 6 months. Subgroup analysis showed stronger effects in patients with irritable bowel syndrome (IBS) (SMD = -1.06) than in those with neurological/psychiatric-related conditions (SMD = -0.67), with moderate heterogeneity (I² = 47%). Conclusions: This meta-analysis supports FMT as an effective adjunctive therapy for depressive symptoms, especially in individuals with IBS. Endoscopic or enema routes appear more efficacious than oral capsules. While short-and mid-term benefits are evident, sustained effects require further investigation through long-term, high-quality RCTs.

Keywords: Depression, depressive symptoms, fecal microbiota transplantation, microbiota, Systematic review, Meta-analysis

Received: 01 Jul 2025; Accepted: 25 Aug 2025.

Copyright: © 2025 Zhang, Li, Guo, Sun and Yang. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) or licensor are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.

* Correspondence: Yue yue Guo, Jiangsu Province Hospital of Chinese Medicine, Nanjing, China

Disclaimer: All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.